ArticleTranslational gastroenterology and hepatology2026
Neutrophil-to-lymphocyte ratio and reversal of decompensation in primary biliary cholangitis: a retrospective cohort study.
Article in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatic recompensation can be achieved in a subset of patients with decompensated primary biliary cholangitis (PBC) following standard therapy. However, reliable early predictors for this clinically significant outcome remain elusive. This study assessed the association of the neutrophil-to-lymphocyte ratio (NLR) with hepatic recompensation in decompensated PBC. Methods: Of 736 consecutive patients diagnosed with decompensated PBC and undergoing standard therapy were included in this retrospective cohort study. The NLR was calculated from baseline hematological parameters. The primary outcome was hepatic recompensation. We assessed the impact of NLR on the incidence of recompensation using Cox regression, with robustness evaluated through subgroup, sensitivity, and trend analyses. Results: Among the 404 decompensated PBC patients (median age 61.0 years; 83.4% female), 114 (28.2%) achieved hepatic recompensation during follow-up. Multivariate analysis demonstrated that a higher NLR was independently associated with a reduced probability of hepatic recompensation [hazard ratio (HR): 0.88, 95% confidence interval (CI): 0.79-0.99, P=0.03]. A significant linear trend for this inverse association was observed (HR: 0.72, 95% CI: 0.56-0.93, P for trend =0.01). Furthermore, subgroup analyses confirmed that this association remained consistent across patients with ascites (HR: 0.88, 95% CI: 0.78-0.99, P=0.03), without ascites (HR: 0.66, 95% CI: 0.48-0.92, P=0.01), and with bleeding (HR: 0.52, 95% CI: 0.34-0.80, P=0.003). Conclusions: NLR is independently associated with hepatic recompensation in PBC and may serve as a potential biomarker forindividualized clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.